Galapagos NV (GLPG) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

31.88 k

Shareholding (Mar 2024)

FII

0.00%

Held by 1 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Operating profit has grown by an annual rate -205.00% of over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -52.79
INTEREST(HY) At EUR 1.31 MM has Grown at 154.37%
OPERATING PROFIT(Q) Lowest at EUR -44.04 MM
OPERATING PROFIT MARGIN(Q) Lowest at -165.14 %

Risky -

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

EUR 1,724 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.45

Return on Equity

-9.77%

Price to Book

0.70

Revenue and Profits:

Net Sales:

65 Million

(Quarterly Results - Jun 2025)

Net Profit:

-104 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-0.37%

6 Months

9.5%

1 Year

5.26%

2 Years

-25.44%

3 Years

-24.63%

4 Years

-37.33%

5 Years

-72.16%

Galapagos NV for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-21.38%

EBIT Growth (5y)

-205.00%

EBIT to Interest (avg)

-52.79

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.20

Sales to Capital Employed (avg)

0.20

Tax Ratio

1.67%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.07%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.74

EV to EBIT

3.09

EV to EBITDA

3.09

EV to Capital Employed

2.46

EV to Sales

-4.17

PEG Ratio

Dividend Yield

ROCE (Latest)

79.60%

ROE (Latest)

-10.91%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2024

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -12.93% vs -0.66% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 32.41% vs -909.42% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "65.30",
          "val2": "75.00",
          "chgp": "-12.93%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-65.40",
          "val2": "-165.30",
          "chgp": "60.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.60",
          "val2": "0.80",
          "chgp": "-25.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-104.50",
          "val2": "-154.60",
          "chgp": "32.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,001.20%",
          "val2": "-2,204.70%",
          "chgp": "120.35%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 14.98% vs -0.62% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 67.50% vs 94.40% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "275.60",
          "val2": "239.70",
          "chgp": "14.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-183.60",
          "val2": "-91.90",
          "chgp": "-99.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.70",
          "val2": "2.60",
          "chgp": "-34.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "72.50",
          "val2": "30.30",
          "chgp": "139.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.30",
          "val2": "-4.00",
          "chgp": "67.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-826.70%",
          "val2": "-533.50%",
          "chgp": "-29.32%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

65.30

75.00

-12.93%

Operating Profit (PBDIT) excl Other Income

-65.40

-165.30

60.44%

Interest

0.60

0.80

-25.00%

Exceptional Items

0.00

Consolidate Net Profit

-104.50

-154.60

32.41%

Operating Profit Margin (Excl OI)

-1,001.20%

-2,204.70%

120.35%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is -12.93% vs -0.66% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 32.41% vs -909.42% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

275.60

239.70

14.98%

Operating Profit (PBDIT) excl Other Income

-183.60

-91.90

-99.78%

Interest

1.70

2.60

-34.62%

Exceptional Items

72.50

30.30

139.27%

Consolidate Net Profit

-1.30

-4.00

67.50%

Operating Profit Margin (Excl OI)

-826.70%

-533.50%

-29.32%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 14.98% vs -0.62% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 67.50% vs 94.40% in Dec 2023

All Annual Results

Company CV

About Galapagos NV

Galapagos NV

Pharmaceuticals & Biotechnology

Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.

Company Coordinates

Company Details

Generaal De Wittelaan 3 , MALINES (MECHELEN) None : 2800

Tel: 32 15 342900

http://www.glpg.com

Registrar Details